Claybrook Capital’s Abiomed Inc ABMD Stock Holding History

Claybrook Capital’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-64	Closed	-$21K	–	742
2018 Q4	$21K	Buy	+64	New	+$22.2K	0.01%	349

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Claybrook Capital's ABMD Position: Q1 2019 in Review

Claybrook Capital sold out of Abiomed Inc (ABMD) in Q1 2019, closing a stake of 64 shares — an estimated $21K sold.

Claybrook Capital first reported a position in ABMD in Q4 2018 and held it in 1 quarter. The position peaked at $21K in Q4 2018. 559 funds tracked by Wall St. Rank hold ABMD as of Q1 2019.

Claybrook Capital reported no remaining Abiomed Inc position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 64 Abiomed Inc shares in Q1 2019, an estimated $21K.
Claybrook Capital first reported a position in Abiomed Inc in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Abiomed Inc position peaked at $21K in Q4 2018.
559 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.